The author could not find a report that describes this co-occurrence in clinical samples however a recent mouse study demonstrated that KMT2D functions as tumor suppressor in BRAF V600E mutant melanomas (Maitituoheti et al., 2020). This evidence concerns the gene BRAF and neoplasm.